These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38751776)

  • 1. ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.
    Orman MV; Sreekanth V; Laajala TD; Cramer SD; Costello JC
    Front Pharmacol; 2024; 15():1360352. PubMed ID: 38751776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
    Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
    EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of
    Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
    Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
    Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
    Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
    Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
    JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
    Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
    Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
    Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
    Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.
    Ren S; Wei GH; Liu D; Wang L; Hou Y; Zhu S; Peng L; Zhang Q; Cheng Y; Su H; Zhou X; Zhang J; Li F; Zheng H; Zhao Z; Yin C; He Z; Gao X; Zhau HE; Chu CY; Wu JB; Collins C; Volik SV; Bell R; Huang J; Wu K; Xu D; Ye D; Yu Y; Zhu L; Qiao M; Lee HM; Yang Y; Zhu Y; Shi X; Chen R; Wang Y; Xu W; Cheng Y; Xu C; Gao X; Zhou T; Yang B; Hou J; Liu L; Zhang Z; Zhu Y; Qin C; Shao P; Pang J; Chung LWK; Xu J; Wu CL; Zhong W; Xu X; Li Y; Zhang X; Wang J; Yang H; Wang J; Huang H; Sun Y
    Eur Urol; 2018 Mar; 73(3):322-339. PubMed ID: 28927585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
    Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
    Calvo A; Perez-Stable C; Segura V; Catena R; Guruceaga E; Nguewa P; Blanco D; Parada L; Reiner T; Green JE
    Prostate; 2010 May; 70(6):630-45. PubMed ID: 20058236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct subtypes of genomic
    Vidotto T; Tiezzi DG; Squire JA
    Mol Cytogenet; 2018; 11():1. PubMed ID: 29308088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
    Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
    Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
    Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
    Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
    Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.
    Madden SF; Clarke C; Gaule P; Aherne ST; O'Donovan N; Clynes M; Crown J; Gallagher WM
    Breast Cancer Res; 2013; 15(4):R52. PubMed ID: 23820017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
    Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer.
    Nunez SK; Young CD; Griffen TL; Ohandjo AQ; McKinney LP; Kopetz S; Lillard JW
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.